Glyphosate Facts

Transparency on safety aspects and use of glyphosate-containing herbicides in Europe

Menu
Search

EPA screening programme indicates that glyphosate does not have endocrine disrupting properties

The Environmental Protection Agency (EPA) in the United States has published the results of its Endocrine Disruptor Screening Programme (EDSP). Results of the assessment indicate that glyphosate does not have endocrine disrupting properties. 

A 'Tier 1' assessment conducted by the EPA evaluated a group of chemicals including glyphosate, with a view to identifying substances which had potential to interact with endocrine (hormone) systems. © iStock.com/ kokouu Based on a weight of evidence analysis, the evaluation found that “glyphosate demonstrates no convincing evidence of potential interaction with oestrogen, androgen or thyroid pathways in mammals or wildlife1”. The EDSP encompasses a second phase, Tier 22, which aims provide a comprehensive assessment of the biological consequences of actual exposure. Since no convincing evidence of potential interaction with endocrine pathways was apparent in the first phase, Tier 2 testing was not recommended for glyphosate.

The findings of the EPA are consistent with those of the Renewal Assessment Report (RAR) recently prepared by Germany as Rapporteur Member State for the EU review of the approval of glyphosate, in so far as no toxic effects on hormone producing or directly hormone dependant organs have been noted in the huge number of toxicological studies reviewed.

1 EDSP Weight of Evidence Conclusions on the Tier 1 Screening Assays for the List 1 Chemicals.
2 In the case of substances found in Tier 1 testing to have endocrine disrupting potential, Tier 2 testing is intended to identify whether, or not, there is an interaction with the endocrine system and to establish a quantitative, dose-response relationship for any adverse effects that might result from that interaction.
 
Further information can be found at the links below:
Read the glyphosate weight of evidence review
Read more about the Endocrine Disruptor Screening Program
 

Last update: 27 July 2015